Entries by Michael Kuhrt

Glythera appoints Chief Scientific Officer

Glythera Limited is pleased to announce the appointment of Dr Robert Lutz as Chief Scientific Officer. Dr Lutz will lead the advancement of Glythera’s portfolio of Antibody Drug Conjugates (ADCs) in the treatment of difficult-to-treat cancers. In addition, Glythera has appointed Dr Jon Roffey to the company’s Scientific Advisory Board (SAB).

Sanifit appoints Cris Calsada as CFO

Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced the appointment of Cris Calsada as Chief Financial Officer.

Biotech enabling Europe to reach UN SDGs

The UN Sustainable Development Goals (SDGs) provide a powerful blueprint for coordinating global efforts to end poverty through economic growth, reducing inequality, and providing better education, health, job opportunities, and environmental protection.

A suited approach to rare disease trials

OPIS   Accelerated approval for orphan drugs and the possibility to have market authorisation
after a successful Phase II trial have made research in rare diseases more attractive to sponsors.
However, challenges and uncertainties remain numerous and designing scientifi cally robust,
patient-centered trials requires proper conceptualisation.

“We have mixed feelings…”

Unitary Patent:?Ingve Stjerna, plaintiff before the Federal Constitutional Court, argues that the UPC system does not deliver on its promise to make European patents cheaper and more affordable to Small and Medium-sized Enterprises (SMEs). European Biotechnology asked José Pfizer, Head of Intellectual Property at 4SC AG, to address the issue from the perspective of a German SME. 

Streamlining Digital Engagement with HCPs

Today, there are greater expectations among healthcare providers for engagement with life sciences companies to be digital. For life sciences companies, there is significant potential to leverage digital technologies to reach more HCPs.